These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20630128)

  • 1. Serum alkaline phosphatase and mortality in hemodialysis patients.
    Beddhu S; Baird B; Ma X; Cheung AK; Greene T
    Clin Nephrol; 2010 Aug; 74(2):91-6. PubMed ID: 20630128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.
    Wang M; Obi Y; Streja E; Rhee CM; Lau WL; Chen J; Hao C; Hamano T; Kovesdy CP; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1118-1127. PubMed ID: 28487345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease.
    Beddhu S; Ma X; Baird B; Cheung AK; Greene T
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1805-10. PubMed ID: 19729429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
    Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS;
    PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death.
    Blayney MJ; Pisoni RL; Bragg-Gresham JL; Bommer J; Piera L; Saito A; Akiba T; Keen ML; Young EW; Port FK
    Kidney Int; 2008 Sep; 74(5):655-63. PubMed ID: 18547993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alkaline phosphatase and mortality in patients on peritoneal dialysis.
    Liu X; Guo Q; Feng X; Wang J; Wu J; Mao H; Huang F; Yu X; Yang X
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):771-8. PubMed ID: 24458081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.
    Rhee CM; Molnar MZ; Lau WL; Ravel V; Kovesdy CP; Mehrotra R; Kalantar-Zadeh K
    Perit Dial Int; 2014; 34(7):732-48. PubMed ID: 24385335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetuin-A as a risk factor for mortality in hemodialysis patients.
    Pecovnik Balon B; Knehtl M; Bevc S; Jakopin E; Gorenjak M
    Wien Klin Wochenschr; 2010 May; 122 Suppl 2():63-7. PubMed ID: 20517675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
    Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study.
    Wald R; Sarnak MJ; Tighiouart H; Cheung AK; Levey AS; Eknoyan G; Miskulin DC
    Am J Kidney Dis; 2008 Sep; 52(3):531-40. PubMed ID: 18657891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients.
    Kobayashi I; Shidara K; Okuno S; Yamada S; Imanishi Y; Mori K; Ishimura E; Shoji S; Yamakawa T; Inaba M
    Life Sci; 2012 Jan; 90(5-6):212-8. PubMed ID: 22154904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients.
    Merle E; Roth H; London GM; Jean G; Hannedouche T; Bouchet JL; Drüeke T; Fouque D; Daugas E;
    Kidney Int; 2016 Mar; 89(3):666-74. PubMed ID: 26880460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone alkaline phosphatase and mortality in dialysis patients.
    Drechsler C; Verduijn M; Pilz S; Krediet RT; Dekker FW; Wanner C; Ketteler M; Boeschoten EW; Brandenburg V;
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1752-9. PubMed ID: 21597029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined alkaline phosphatase and phosphorus levels as a predictor of mortality in maintenance hemodialysis patients.
    Chang JF; Feng YF; Peng YS; Hsu SP; Pai MF; Chen HY; Wu HY; Yang JY
    Medicine (Baltimore); 2014 Oct; 93(18):e106. PubMed ID: 25319440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.
    Scialla JJ; Parekh RS; Eustace JA; Astor BC; Plantinga L; Jaar BG; Shafi T; Coresh J; Powe NR; Melamed ML
    Am J Nephrol; 2015; 42(1):25-34. PubMed ID: 26287973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Alkaline Phosphatase Levels are Not Associated with Increased Death Risk in Prevalent Hemodialysis Patients: 5-Year Experience in a Single Hemodialysis Center.
    Zhu JG; Cheng BC; Lee WC; Li LC; Lee CH; Long G; Chen JB
    Kidney Blood Press Res; 2016; 41(4):498-506. PubMed ID: 27467278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.
    Regidor DL; Kovesdy CP; Mehrotra R; Rambod M; Jing J; McAllister CJ; Van Wyck D; Kopple JD; Kalantar-Zadeh K
    J Am Soc Nephrol; 2008 Nov; 19(11):2193-203. PubMed ID: 18667733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012.
    Liu CT; Lin YC; Lin YC; Kao CC; Chen HH; Hsu CC; Wu MS
    Sci Rep; 2017 Feb; 7(1):33. PubMed ID: 28232731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients.
    Al-Hilali N; Al-Humoud H; Al-Helal B; Al-Azmi M; Al-Kandari NH; Johny KV
    Ther Apher Dial; 2008 Apr; 12(2):137-42. PubMed ID: 18387162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.